v3.26.1
Collaboration, License and Option Agreements (Tables)
3 Months Ended
Mar. 31, 2026
Collaboration and License Agreements  
Schedule of changes in the balances of contract liabilities

The following table presents changes in the balances of the Company's contract liabilities:

 

 

 

Gilead

 

 

AbbVie

 

 

Total

 

Deferred revenue as of December 31, 2025

 

$

 

26,651

 

 

$

 

34,007

 

 

$

 

60,658

 

Collaboration and license revenue recognized

 

 

 

(4,653

)

 

 

 

(7,995

)

 

 

 

(12,648

)

Deferred revenue as of March 31, 2026

 

$

 

21,998

 

 

$

 

26,012

 

 

$

 

48,010